Posted by Michael Wonder on 16 May 2025
Amneal receives US FDA approval for Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine and cluster headaches in adults
15 May 2025 - Product will be available for appropriate patients in the second half of 2025
Amneal Pharmaceuticals today announced that the US FDA has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine auto-injector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
